Applied Clinical Trials
Applied Clinical Trials-08-01-2013
Volume: 22
Issue: 8
Applied Clinical Trials Digital Edition-07-01-2013
Issue: 7
Applied Clinical Trials-06-01-2013
Volume: 22
Issue: 6
Applied Clinical Trials Digital Edition-06-01-2013
Volume: 22
Issue: 6
Applied Clinical Trials-05-01-2013
Volume: 22
Issue: 5
Applied Clinical Trials Digital Edition-05-01-2013
Volume: 22
Issue: 5
Applied Clinical Trials Digital Edition-05-02-2013
Issue: 5
Applied Clinical Trials-04-01-2013
Volume: 22
Issue: 4
Applied Clinical Trials Digital Edition-04-02-2013
Issue: 4
Applied Clinical Trials Digital Edition-04-01-2013
Volume: 22
Issue: 4
Applied Clinical Trials-03-01-2013
Volume: 22
Issue: 3
Applied Clinical Trials Digital Edition-03-01-2013
Volume: 22
Issue: 3
Applied Clinical Trials-02-01-2013
Volume: 22
Issue: 2
Applied Clinical Trials Digital Edition-02-01-2013
Volume: 0
Issue: 0
Applied Clinical Trials-01-01-2013
Volume: 22
Issue: 1
Applied Clinical Trials Digital Edition-01-01-2013
Volume: 0
Issue: 0
Applied Clinical Trials-12-01-2012
Volume: 21
Issue: 12
Applied Clinical Trials Digital Edition-12-01-2012
Volume: 0
Issue: 0
Applied Clinical Trials-11-01-2012
Volume: 21
Issue: 11
Applied Clinical Trials Digital Edition-11-01-2012
Volume: 0
Issue: 0
Applied Clinical Trials-10-01-2012
Volume: 21
Issue: 10
Applied Clinical Trials Digital Edition-10-01-2012
Volume: 0
Issue: 0
Applied Clinical Trials-09-01-2012
Volume: 21
Issue: 9
Applied Clinical Trials Digital Edition-09-01-2012
Volume: 0
Issue: 0
Applied Clinical Trials-08-01-2012
Volume: 21
Issue: 8
Applied Clinical Trials Digital Edition-08-01-2012
Volume: 0
Issue: 0
Applied Clinical Trials-07-01-2012
Volume: 21
Issue: 7
Applied Clinical Trials Digital Edition-07-01-2012
Volume: 0
Issue: 0
Applied Clinical Trials-06-01-2012
Volume: 21
Issue: 6
Applied Clinical Trials Digital Edition-06-01-2012
Volume: 0
Issue: 0
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
2
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
3
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation
4
Designing Feasible Protocols with Real-World Data
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
